nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Bone disorder—Methotrexate—colon cancer	0.00332	0.00332	CcSEcCtD
Tobramycin—Swelling—Capecitabine—colon cancer	0.00332	0.00332	CcSEcCtD
Tobramycin—Renal failure—Irinotecan—colon cancer	0.00331	0.00331	CcSEcCtD
Tobramycin—Stomatitis—Irinotecan—colon cancer	0.00328	0.00328	CcSEcCtD
Tobramycin—Deafness—Capecitabine—colon cancer	0.00327	0.00327	CcSEcCtD
Tobramycin—Oliguria—Methotrexate—colon cancer	0.00326	0.00326	CcSEcCtD
Tobramycin—Eye pain—Capecitabine—colon cancer	0.00324	0.00324	CcSEcCtD
Tobramycin—Infestation—Fluorouracil—colon cancer	0.00323	0.00323	CcSEcCtD
Tobramycin—Infestation NOS—Fluorouracil—colon cancer	0.00323	0.00323	CcSEcCtD
Tobramycin—Renal failure acute—Capecitabine—colon cancer	0.00317	0.00317	CcSEcCtD
Tobramycin—Neuropathy peripheral—Fluorouracil—colon cancer	0.00316	0.00316	CcSEcCtD
Tobramycin—Stomatitis—Fluorouracil—colon cancer	0.00314	0.00314	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Capecitabine—colon cancer	0.0031	0.0031	CcSEcCtD
Tobramycin—Renal impairment—Capecitabine—colon cancer	0.00307	0.00307	CcSEcCtD
Tobramycin—Urinary tract disorder—Vincristine—colon cancer	0.00307	0.00307	CcSEcCtD
Tobramycin—Connective tissue disorder—Vincristine—colon cancer	0.00305	0.00305	CcSEcCtD
Tobramycin—Urethral disorder—Vincristine—colon cancer	0.00304	0.00304	CcSEcCtD
Tobramycin—Epistaxis—Fluorouracil—colon cancer	0.00304	0.00304	CcSEcCtD
Tobramycin—Rhinitis—Irinotecan—colon cancer	0.00303	0.00303	CcSEcCtD
Tobramycin—Sinusitis—Fluorouracil—colon cancer	0.00303	0.00303	CcSEcCtD
Tobramycin—Agranulocytosis—Fluorouracil—colon cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Lethargy—Capecitabine—colon cancer	0.00299	0.00299	CcSEcCtD
Tobramycin—Connective tissue disorder—Irinotecan—colon cancer	0.00297	0.00297	CcSEcCtD
Tobramycin—Visual impairment—Irinotecan—colon cancer	0.00291	0.00291	CcSEcCtD
Tobramycin—Rhinitis—Fluorouracil—colon cancer	0.0029	0.0029	CcSEcCtD
Tobramycin—Pharyngitis—Fluorouracil—colon cancer	0.00287	0.00287	CcSEcCtD
Tobramycin—Angiopathy—Vincristine—colon cancer	0.00282	0.00282	CcSEcCtD
Tobramycin—Mediastinal disorder—Vincristine—colon cancer	0.0028	0.0028	CcSEcCtD
Tobramycin—Angiopathy—Irinotecan—colon cancer	0.00274	0.00274	CcSEcCtD
Tobramycin—Blood creatinine increased—Capecitabine—colon cancer	0.00274	0.00274	CcSEcCtD
Tobramycin—Immune system disorder—Irinotecan—colon cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Mediastinal disorder—Irinotecan—colon cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Dehydration—Capecitabine—colon cancer	0.00272	0.00272	CcSEcCtD
Tobramycin—Dry skin—Capecitabine—colon cancer	0.00268	0.00268	CcSEcCtD
Tobramycin—Hypokalaemia—Capecitabine—colon cancer	0.00266	0.00266	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Back pain—Vincristine—colon cancer	0.00261	0.00261	CcSEcCtD
Tobramycin—Muscular weakness—Capecitabine—colon cancer	0.00258	0.00258	CcSEcCtD
Tobramycin—Back pain—Irinotecan—colon cancer	0.00255	0.00255	CcSEcCtD
Tobramycin—Asthma—Capecitabine—colon cancer	0.00253	0.00253	CcSEcCtD
Tobramycin—Erythema—Fluorouracil—colon cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Thrombophlebitis—Methotrexate—colon cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Anaemia—Vincristine—colon cancer	0.0025	0.0025	CcSEcCtD
Tobramycin—Bronchospasm—Capecitabine—colon cancer	0.00249	0.00249	CcSEcCtD
Tobramycin—Ill-defined disorder—Irinotecan—colon cancer	0.00244	0.00244	CcSEcCtD
Tobramycin—Anaemia—Irinotecan—colon cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Bronchitis—Capecitabine—colon cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Vertigo—Vincristine—colon cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Leukopenia—Vincristine—colon cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Vision blurred—Fluorouracil—colon cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Malaise—Irinotecan—colon cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Vertigo—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—colon cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Leukopenia—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Capecitabine—colon cancer	0.00235	0.00235	CcSEcCtD
Tobramycin—Anaemia—Fluorouracil—colon cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—colon cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Myalgia—Vincristine—colon cancer	0.0023	0.0023	CcSEcCtD
Tobramycin—Cough—Irinotecan—colon cancer	0.0023	0.0023	CcSEcCtD
Tobramycin—Weight decreased—Capecitabine—colon cancer	0.00229	0.00229	CcSEcCtD
Tobramycin—Leukopenia—Fluorouracil—colon cancer	0.00226	0.00226	CcSEcCtD
Tobramycin—Infestation—Capecitabine—colon cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Infestation NOS—Capecitabine—colon cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—colon cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Renal failure—Capecitabine—colon cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Discomfort—Irinotecan—colon cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Neuropathy peripheral—Capecitabine—colon cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Anaphylactic shock—Vincristine—colon cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Stomatitis—Capecitabine—colon cancer	0.0022	0.0022	CcSEcCtD
Tobramycin—Confusional state—Irinotecan—colon cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Nervous system disorder—Vincristine—colon cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Thrombocytopenia—Vincristine—colon cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Anaphylactic shock—Irinotecan—colon cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Myalgia—Fluorouracil—colon cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Chest pain—Fluorouracil—colon cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Epistaxis—Capecitabine—colon cancer	0.00213	0.00213	CcSEcCtD
Tobramycin—Discomfort—Fluorouracil—colon cancer	0.00212	0.00212	CcSEcCtD
Tobramycin—Nervous system disorder—Irinotecan—colon cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Agranulocytosis—Capecitabine—colon cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Thrombocytopenia—Irinotecan—colon cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Anorexia—Vincristine—colon cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Confusional state—Fluorouracil—colon cancer	0.00207	0.00207	CcSEcCtD
Tobramycin—Anaphylactic shock—Fluorouracil—colon cancer	0.00206	0.00206	CcSEcCtD
Tobramycin—Anorexia—Irinotecan—colon cancer	0.00205	0.00205	CcSEcCtD
Tobramycin—Rhinitis—Capecitabine—colon cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Nervous system disorder—Fluorouracil—colon cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Thrombocytopenia—Fluorouracil—colon cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Vincristine—colon cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Pharyngitis—Capecitabine—colon cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Urinary tract disorder—Capecitabine—colon cancer	0.002	0.002	CcSEcCtD
Tobramycin—Connective tissue disorder—Capecitabine—colon cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Urethral disorder—Capecitabine—colon cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Paraesthesia—Vincristine—colon cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Anorexia—Fluorouracil—colon cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Visual impairment—Capecitabine—colon cancer	0.00195	0.00195	CcSEcCtD
Tobramycin—Paraesthesia—Irinotecan—colon cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Decreased appetite—Vincristine—colon cancer	0.00192	0.00192	CcSEcCtD
Tobramycin—Dyspnoea—Irinotecan—colon cancer	0.00192	0.00192	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Vincristine—colon cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Eye disorder—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Tinnitus—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Pain—Vincristine—colon cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Asthma—Methotrexate—colon cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00187	0.00187	CcSEcCtD
Tobramycin—Decreased appetite—Irinotecan—colon cancer	0.00187	0.00187	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—colon cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Irinotecan—colon cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Paraesthesia—Fluorouracil—colon cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Pain—Irinotecan—colon cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Angiopathy—Capecitabine—colon cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Dyspnoea—Fluorouracil—colon cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Immune system disorder—Capecitabine—colon cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Mediastinal disorder—Capecitabine—colon cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Gastrointestinal pain—Vincristine—colon cancer	0.0018	0.0018	CcSEcCtD
Tobramycin—Decreased appetite—Fluorouracil—colon cancer	0.00179	0.00179	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Feeling abnormal—Irinotecan—colon cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Erythema—Capecitabine—colon cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Pain—Fluorouracil—colon cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Gastrointestinal pain—Irinotecan—colon cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—colon cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Abdominal pain—Vincristine—colon cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Body temperature increased—Vincristine—colon cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Dysgeusia—Capecitabine—colon cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Back pain—Capecitabine—colon cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Abdominal pain—Irinotecan—colon cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Body temperature increased—Irinotecan—colon cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Feeling abnormal—Fluorouracil—colon cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—colon cancer	0.00168	0.00168	CcSEcCtD
Tobramycin—Infestation—Methotrexate—colon cancer	0.00168	0.00168	CcSEcCtD
Tobramycin—Vision blurred—Capecitabine—colon cancer	0.00166	0.00166	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—colon cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—colon cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Ill-defined disorder—Capecitabine—colon cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Urticaria—Fluorouracil—colon cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Anaemia—Capecitabine—colon cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Body temperature increased—Fluorouracil—colon cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Hypersensitivity—Vincristine—colon cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Malaise—Capecitabine—colon cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—colon cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Vertigo—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Hypersensitivity—Irinotecan—colon cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Asthenia—Vincristine—colon cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Leukopenia—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—colon cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Asthenia—Irinotecan—colon cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Cough—Capecitabine—colon cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Hypersensitivity—Fluorouracil—colon cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Diarrhoea—Vincristine—colon cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Myalgia—Capecitabine—colon cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Chest pain—Capecitabine—colon cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—colon cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—colon cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Discomfort—Capecitabine—colon cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—colon cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Diarrhoea—Irinotecan—colon cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Dizziness—Vincristine—colon cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Pruritus—Fluorouracil—colon cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—colon cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Confusional state—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Dizziness—Irinotecan—colon cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Nervous system disorder—Capecitabine—colon cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—colon cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Diarrhoea—Fluorouracil—colon cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Thrombocytopenia—Capecitabine—colon cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—colon cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Vomiting—Vincristine—colon cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Skin disorder—Capecitabine—colon cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Rash—Vincristine—colon cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Dermatitis—Vincristine—colon cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Headache—Vincristine—colon cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Anorexia—Capecitabine—colon cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—colon cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Vomiting—Irinotecan—colon cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—colon cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Dizziness—Fluorouracil—colon cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—colon cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Rash—Irinotecan—colon cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Dermatitis—Irinotecan—colon cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Headache—Irinotecan—colon cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Erythema—Methotrexate—colon cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Nausea—Vincristine—colon cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Vomiting—Fluorouracil—colon cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Rash—Fluorouracil—colon cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Dermatitis—Fluorouracil—colon cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Paraesthesia—Capecitabine—colon cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Headache—Fluorouracil—colon cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—colon cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Dyspnoea—Capecitabine—colon cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Nausea—Irinotecan—colon cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Back pain—Methotrexate—colon cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Decreased appetite—Capecitabine—colon cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Capecitabine—colon cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—colon cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Pain—Capecitabine—colon cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Nausea—Fluorouracil—colon cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—colon cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—colon cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Feeling abnormal—Capecitabine—colon cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Malaise—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Gastrointestinal pain—Capecitabine—colon cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Cough—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Urticaria—Capecitabine—colon cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Abdominal pain—Capecitabine—colon cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Body temperature increased—Capecitabine—colon cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—colon cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—colon cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—colon cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—colon cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—colon cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Hypersensitivity—Capecitabine—colon cancer	0.00106	0.00106	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—colon cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—colon cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Asthenia—Capecitabine—colon cancer	0.00103	0.00103	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—colon cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Pruritus—Capecitabine—colon cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Diarrhoea—Capecitabine—colon cancer	0.000984	0.000984	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000975	0.000975	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—colon cancer	0.000961	0.000961	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—colon cancer	0.000954	0.000954	CcSEcCtD
Tobramycin—Dizziness—Capecitabine—colon cancer	0.000951	0.000951	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—colon cancer	0.00093	0.00093	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—colon cancer	0.000924	0.000924	CcSEcCtD
Tobramycin—Pain—Methotrexate—colon cancer	0.000915	0.000915	CcSEcCtD
Tobramycin—Vomiting—Capecitabine—colon cancer	0.000914	0.000914	CcSEcCtD
Tobramycin—Rash—Capecitabine—colon cancer	0.000907	0.000907	CcSEcCtD
Tobramycin—Dermatitis—Capecitabine—colon cancer	0.000906	0.000906	CcSEcCtD
Tobramycin—Headache—Capecitabine—colon cancer	0.000901	0.000901	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—colon cancer	0.000882	0.000882	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—colon cancer	0.000875	0.000875	CcSEcCtD
Tobramycin—Nausea—Capecitabine—colon cancer	0.000854	0.000854	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—colon cancer	0.00085	0.00085	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—colon cancer	0.000846	0.000846	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—colon cancer	0.000846	0.000846	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—colon cancer	0.000789	0.000789	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—colon cancer	0.000768	0.000768	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—colon cancer	0.000757	0.000757	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—colon cancer	0.000732	0.000732	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—colon cancer	0.000708	0.000708	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—colon cancer	0.000681	0.000681	CcSEcCtD
Tobramycin—Rash—Methotrexate—colon cancer	0.000675	0.000675	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—colon cancer	0.000674	0.000674	CcSEcCtD
Tobramycin—Headache—Methotrexate—colon cancer	0.000671	0.000671	CcSEcCtD
Tobramycin—Nausea—Methotrexate—colon cancer	0.000636	0.000636	CcSEcCtD
